

**Basingstoke, Southampton and Winchester
District Prescribing Committee (DPC)**

Recommendations of the meeting of Tuesday 9 April 2019

Supported or limited support e.g. Specialist recommendation

Wound formulary changes- A reminder that Kliniderm-superabsorbent is supported for use as an alternative to Vliwasorb superabsorbent dressing as it has a softer border and is less expensive. There are potential savings across the three CCGs of £110,000 per annum if this change is implemented.

Semaglutide injection – this new, once weekly, GLP-1 analogue is supported for use locally with a recommendation that organisations add to their formularies. It is classified as ‘Green’.

Ciclosporin eye drops (Verkazia) – is supported for use locally and classified as ‘Amber’. It is indicated for the treatment of vernal keratoconjunctivitis in children and adolescents (age 4 to 18 years). This product should replace the off-label use of Ikervis eye drops which are not licensed for use in children. The Committee recommends that ciclosporin eye drops should be prescribed by brand name to avoid confusion.

Ertugliflozin – this new SGLT2 inhibitor is supported for use locally with a recommendation that organisations add to their formularies, classified as ‘Green’. The Committee noted that ertugliflozin is the least expensive SGLT-2 inhibitor. The NICE guidance made the following statement:

If patients and their clinicians consider ertugliflozin to be one of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen.

Not supported

Lixisenatide injection - given that the Committee has supported the availability of semaglutide locally (see above) it is recommended that lixisenatide injection is no longer supported for use locally and that organisations remove this product from their formularies. Patients currently being lixisenatide can continue to be prescribed this product is considered clinically appropriate and effective.

Guidance documents are available [Here](#) (hosted by West Hampshire CCG)

Summarised on behalf of the District Prescribing Committee by Neil Hardy (West Hampshire CCG)